Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) will be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.86 per share for the quarter.
Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) last released its earnings results on Wednesday, January 31st. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.11. Dr. Reddy’s Laboratories had a return on equity of 20.97% and a net margin of 19.26%. The business had revenue of $867.00 million for the quarter, compared to analyst estimates of $827.81 million. On average, analysts expect Dr. Reddy’s Laboratories to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Dr. Reddy’s Laboratories Stock Down 0.9 %
Shares of RDY traded down $0.68 during midday trading on Tuesday, reaching $73.74. 27,351 shares of the stock were exchanged, compared to its average volume of 193,523. Dr. Reddy’s Laboratories has a 52 week low of $53.12 and a 52 week high of $77.72. The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $74.15 and its two-hundred day moving average is $70.54. The company has a market capitalization of $12.31 billion, a P/E ratio of 19.64, a PEG ratio of 1.86 and a beta of 0.58.
Analyst Ratings Changes
View Our Latest Stock Report on Dr. Reddy’s Laboratories
About Dr. Reddy’s Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.
Further Reading
- Five stocks we like better than Dr. Reddy’s Laboratories
- 3 Best Fintech Stocks for a Portfolio Boost
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- How to Use Stock Screeners to Find Stocks
- Hilton Demonstrates Asset Light is Right for Investors
- Options Trading – Understanding Strike Price
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.